Progenity is applying a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its development of a novel pipeline of precision medicine product candidates designed to provide solutions for gastrointestinal disorders. This pipeline includes diagnostic applications, targeted drug delivery in the GI tract at the site of disease, and the oral delivery of biologics. These product candidates, if successfully developed, have the potential to address unmet healthcare needs by more precisely identifying and treating chronic GI diseases, such as small intestinal bacterial overgrowth, or SIBO, and inflammatory bowel disease, or IBD.
Technology Networks talked with Progenity’s Christopher Wahl, MD, MBA and vice president of strategy and operations to get his insights into the research and work being done specifically with Progenity’s novel ingestible lab-in-a-capsule, PIL Dx.